Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GRAINGER PLC. We currently have 50 research reports from 1 professional analysts.
|09Mar17 16:00||RNS||Total Voting Rights|
|08Mar17 11:07||RNS||Director/PDMR Shareholding|
|07Mar17 16:00||RNS||Director/PDMR Shareholding|
|07Mar17 15:56||RNS||Holding(s) in Company|
|06Mar17 11:33||RNS||Director/PDMR Shareholding|
|03Mar17 16:09||RNS||Holding(s) in Company|
|01Mar17 07:00||RNS||Notice of Interim Results|
Frequency of research reports
Research reports on
N+1 Singer - Grainger - Positive start to FY17e, rental growth continues
08 Feb 17
Grainger has reported a solid start to the new financial year (4 months incl. Q1 and January) with continued rental growth and sales of vacant properties modestly ahead of HPI in the period. Positive progress has been made on PRS assets under development, with planning permission received on a 242 unit site in Leeds last week. Grainger highlights a positive impact from the Housing White Paper: the revised planning framework favouring affordable rent. We reiterate our BUY recommendation and 320p 12m Target Price. The shares continue to trade at a discount (15%) to NNNAV which ignores the value in the reversionary surplus and the opportunity to reinvest capital in yielding PRS.
N+1 Singer - Morning Song 08-02-2017
08 Feb 17
blur Group (BLUR LN) Trading update and first enterprise subscription | First Derivatives (FDP LN) Strategic investment partnership, target price increased | Grainger (GRI LN) Positive start to FY17e, rental growth continues | Victrex (VCT LN) Solid Q1, shine taken off by medical
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 01-12-2016
01 Dec 16
Blackstone/GSO Loan Financing (BGLF LN) CLO refinancing outlook | Clipper Logistics (CLG LN) Interims highlight further significant growth | Grainger (GRI LN) Final results in line, further progress on PRS investment pipeline | Vernalis (VER LN) AGM statement in line with expectations | WYG (WYG LN) Order book strength underpins FY expectations
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.